Derleme
BibTex RIS Kaynak Göster

Lipodistrofili hastalarda insülin tedavisinin incelikleri

Yıl 2023, Cilt: 62 Sayı: 1, 158 - 162, 15.03.2023

Ilgin Yildirim Simsir Utku Erdem Soyaltin Sevki Cetinkalp Baris Akinci

https://doi.org/10.19161/etd.1262624

Öz

Lipodistrofi (LD) hastalarında insülin direnci temelinde gelişen Diabetes Mellitus (DM) tedavisinde
sıklıkla yüksek doz insüline ihtiyaç duyulur. Pratikte sıklıkla uygulanan kan şekeri normalleşmesini
sağlamak için insülin dozlarını kademeli olarak arttırmaktır.
Yüksek insülin dozlarının daha büyük enjeksiyon hacmi gerektirmesi, insülinin subkutan dokudan
dolaşıma emiliminde bozulmaya neden olur.
Bu yazıda, LD'li hastalarda DM tedavisinde insülin uygulamasına klinik yaklaşımı tartıştık ve literatürü
sistematik olarak gözden geçirdik.

Anahtar Kelimeler

İnsulin tedavisi lipodistrofi konsantre insülinler.

Kaynakça

  • Oral EA. Lipoatrophic diabetes and other related syndromes. Rev Endocr Metab Disord. 2003; 4 (1): 61-77. https://doi.org/10.1023/a:1021827520301.
  • Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010; 16 (2): 310-23. https://doi.org/10.4158/EP09154.RA.
  • Akinci B, Sahinoz M, Oral A, et al. Lipodystrophy Syndromes: Presentation and Treatment. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2018 Apr 24. PMID: 29989768. https://www.ncbi.nlm.nih.gov/books/NBK513130/
  • Ferrara D, Montecucco F, Dallegri F, et al. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol. 2019; 234 (12): 21630-41. https://doi.org/10.1002/jcp.28821.
  • Binder C. Absorption of injected insulin. A clinicalpharmacological study. Acta Pharmacol Toxicol (Copenh). 1969; 27 (Suppl. 2): 1-84. https://doi.org/10.1111/j.1600-0773.1969.tb03069.x.
  • Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al. Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability. J Diabetes Res. 2018; 2018: 1205121. https://doi.org/10.1155/2018/1205121.
  • Vantyghem MC, Vigouroux C, Magre J, et al. Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog. Diabetes Care. 1999; 22 (8):1374-6. https://doi.org/10.2337/diacare.22.8.1374.
  • Moreau F, Boullu-Sanchis S, Vigouroux C, et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 2007;33(5):385-9. https://doi.org/10.1016/j.diabet.2007.04.005.
  • Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002; 109 (10): 1345-50. https://doi.org/10.1172/JCI15001.
  • Satoh M, Yoshizawa A, Takesue M, et al. Long-term effects of recombinant human insulin-like growth factor I treatment on glucose and lipid metabolism and the growth of a patient with congenital generalized lipodystrophy. Endocr J. 2006; 53 (5): 639-45. https://doi.org/10.1507/endocrj.k06-014.
  • Bagias C, Xiarchou A, Bargiota A, et al. Familial Partial Lipodystrophy (FPLD): Recent Insights. Diabetes Metab Syndr Obes. 2020; 13: 1531-44. https://doi.org/10.2147/DMSO.S206053.
  • Stears A, Hames C. Diagnosis and management of lipodystrophy: a practical update. Clin Lipidol. 2014; 9 (2): 235-9. https://doi.org/10.2217/clp.14.13.
  • Ovalle F. Clinical approach to the patient with diabetes mellitus and very high insulin requirements. Diabetes Res Clin Pract. 2010; 90 (3): 231-42. https://doi.org/10.1016/j.diabres.2010.06.025.
  • American Diabetes Association. Insulin Administration. Diabetes Care 2004; 27(suppl 1): s106-s107. https://doi.org/10.2337/diacare.27.2007.S106.
  • Gonzalvo JD, Patel DK, Olin JL. Concentrated Insulins: A Review and Recommendations. Fed Pract. 2017; 34 (Suppl 8): S38-S43. PMID 30766315.
  • Painter NA, Sisson E. An Overview of Concentrated Insulin Products. Diabetes Spectr. 2016 Aug; 29 (3): 136-40. https://doi.org/10.2337/diaspect.29.3.136.
  • Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014; 16 (6): 483-91. https://doi.org/10.1111/dom.12219.
  • Caparrotta TM, Evans M. PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue. Diabetes Obes Metab. 2014;16(5):388-95. https://doi.org/10.1111/dom.12196.
  • Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71-9. https://doi.org/10.4158/EP.15.1.71.
  • Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240-4. https://doi.org/10.2337/diacare.28.5.1240.
  • Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014; 16 (9): 873-6. https://doi.org/10.1111/dom.12283.
  • Lima JG, Lima NN, Lima RLM, et al. Glargine U300 insulin as a better option than degludec U100 to treat a congenital generalized lipodystrophy patient. Clin Diabetes Res. 2017; 1 (1): 14-5. https://doi.org/10.36959/647/489.
  • Segal AR, Vootla T, Beaser RS. Insulin: making sense of current options. Endocrinol Metab Clin North Am. 2016; 45 (4): 845-74. https://doi.org/10.1016/j.ecl.2016.06.009.
  • Satin LS, Butler PC, Ha J, et al. Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes. Mol Aspects Med. 2015; 42: 61-77. https://doi.org/10.1016/j.mam.2015.01.003.
  • Hirsch IB. Practical pearls in insulin pump therapy. Diabetes Technol Ther. 2010;12 Suppl 1: S23-7. https://doi.org/10.1089/dia.2010.0022.
  • Knee TS, Seidensticker DF, Walton JL, et al. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003; 9 (3): 181-6. https://doi.org/10.4158/EP.9.3.181.
  • Wilson LM, Castle JR. Recent Advances in Insulin Therapy. Diabetes Technol Ther. 2020; 22 (12): 929-36. https://doi.org/10.1089/dia.2020.0065

The subtleties of insulin treatment in patients with lipodystrophy

Yıl 2023, Cilt: 62 Sayı: 1, 158 - 162, 15.03.2023

Ilgin Yildirim Simsir Utku Erdem Soyaltin Sevki Cetinkalp Baris Akinci

https://doi.org/10.19161/etd.1262624

Öz

In the treatment of Diabetes Mellitus (DM), which develops on the basis of insulin resistance in
patients with lipodystrophy (LD) often require high doses of insulin. Traditionally in practice is to
gradually increase the insulin doses to achieve blood glucose normalization.
The fact that high insulin doses require a larger injection volume, which causes impairment in the
absorption of insulin from the subcutaneous tissue to the circulation.
In this article, we discussed the clinical approach to insulin practice in the treatment of DM in patients
with LD and reviewed systematically the literature.

Anahtar Kelimeler

İnsulin treatment lipodystrophy concentrated insulins.

Kaynakça

  • Oral EA. Lipoatrophic diabetes and other related syndromes. Rev Endocr Metab Disord. 2003; 4 (1): 61-77. https://doi.org/10.1023/a:1021827520301.
  • Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010; 16 (2): 310-23. https://doi.org/10.4158/EP09154.RA.
  • Akinci B, Sahinoz M, Oral A, et al. Lipodystrophy Syndromes: Presentation and Treatment. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2018 Apr 24. PMID: 29989768. https://www.ncbi.nlm.nih.gov/books/NBK513130/
  • Ferrara D, Montecucco F, Dallegri F, et al. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol. 2019; 234 (12): 21630-41. https://doi.org/10.1002/jcp.28821.
  • Binder C. Absorption of injected insulin. A clinicalpharmacological study. Acta Pharmacol Toxicol (Copenh). 1969; 27 (Suppl. 2): 1-84. https://doi.org/10.1111/j.1600-0773.1969.tb03069.x.
  • Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al. Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability. J Diabetes Res. 2018; 2018: 1205121. https://doi.org/10.1155/2018/1205121.
  • Vantyghem MC, Vigouroux C, Magre J, et al. Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog. Diabetes Care. 1999; 22 (8):1374-6. https://doi.org/10.2337/diacare.22.8.1374.
  • Moreau F, Boullu-Sanchis S, Vigouroux C, et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 2007;33(5):385-9. https://doi.org/10.1016/j.diabet.2007.04.005.
  • Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002; 109 (10): 1345-50. https://doi.org/10.1172/JCI15001.
  • Satoh M, Yoshizawa A, Takesue M, et al. Long-term effects of recombinant human insulin-like growth factor I treatment on glucose and lipid metabolism and the growth of a patient with congenital generalized lipodystrophy. Endocr J. 2006; 53 (5): 639-45. https://doi.org/10.1507/endocrj.k06-014.
  • Bagias C, Xiarchou A, Bargiota A, et al. Familial Partial Lipodystrophy (FPLD): Recent Insights. Diabetes Metab Syndr Obes. 2020; 13: 1531-44. https://doi.org/10.2147/DMSO.S206053.
  • Stears A, Hames C. Diagnosis and management of lipodystrophy: a practical update. Clin Lipidol. 2014; 9 (2): 235-9. https://doi.org/10.2217/clp.14.13.
  • Ovalle F. Clinical approach to the patient with diabetes mellitus and very high insulin requirements. Diabetes Res Clin Pract. 2010; 90 (3): 231-42. https://doi.org/10.1016/j.diabres.2010.06.025.
  • American Diabetes Association. Insulin Administration. Diabetes Care 2004; 27(suppl 1): s106-s107. https://doi.org/10.2337/diacare.27.2007.S106.
  • Gonzalvo JD, Patel DK, Olin JL. Concentrated Insulins: A Review and Recommendations. Fed Pract. 2017; 34 (Suppl 8): S38-S43. PMID 30766315.
  • Painter NA, Sisson E. An Overview of Concentrated Insulin Products. Diabetes Spectr. 2016 Aug; 29 (3): 136-40. https://doi.org/10.2337/diaspect.29.3.136.
  • Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014; 16 (6): 483-91. https://doi.org/10.1111/dom.12219.
  • Caparrotta TM, Evans M. PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue. Diabetes Obes Metab. 2014;16(5):388-95. https://doi.org/10.1111/dom.12196.
  • Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71-9. https://doi.org/10.4158/EP.15.1.71.
  • Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240-4. https://doi.org/10.2337/diacare.28.5.1240.
  • Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014; 16 (9): 873-6. https://doi.org/10.1111/dom.12283.
  • Lima JG, Lima NN, Lima RLM, et al. Glargine U300 insulin as a better option than degludec U100 to treat a congenital generalized lipodystrophy patient. Clin Diabetes Res. 2017; 1 (1): 14-5. https://doi.org/10.36959/647/489.
  • Segal AR, Vootla T, Beaser RS. Insulin: making sense of current options. Endocrinol Metab Clin North Am. 2016; 45 (4): 845-74. https://doi.org/10.1016/j.ecl.2016.06.009.
  • Satin LS, Butler PC, Ha J, et al. Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes. Mol Aspects Med. 2015; 42: 61-77. https://doi.org/10.1016/j.mam.2015.01.003.
  • Hirsch IB. Practical pearls in insulin pump therapy. Diabetes Technol Ther. 2010;12 Suppl 1: S23-7. https://doi.org/10.1089/dia.2010.0022.
  • Knee TS, Seidensticker DF, Walton JL, et al. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003; 9 (3): 181-6. https://doi.org/10.4158/EP.9.3.181.
  • Wilson LM, Castle JR. Recent Advances in Insulin Therapy. Diabetes Technol Ther. 2020; 22 (12): 929-36. https://doi.org/10.1089/dia.2020.0065
Toplam 27 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Derlemeler
Yazarlar

Ilgin Yildirim Simsir

Utku Erdem Soyaltin

Sevki Cetinkalp

Baris Akinci

Yayımlanma Tarihi 15 Mart 2023
Gönderilme Tarihi 3 Mart 2022
Yayımlandığı Sayı Yıl 2023Cilt: 62 Sayı: 1

Kaynak Göster

Vancouver Yildirim Simsir I, Soyaltin UE, Cetinkalp S, Akinci B. The subtleties of insulin treatment in patients with lipodystrophy. ETD. 2023;62(1):158-62.
 Kapak Resmi İndir

1724617243172472652917240      26515    

 26507    26508 26517265142651826513

2652026519